ImmuneBridge Secures $5.63M Seed Round to Revolutionize Cord Blood Immunotherapies for Cancer

ImmuneBridge, a cutting-edge biotech company dedicated to revolutionizing cancer immunotherapy, proudly announces that it has raised $5,630,000 in a landmark funding round.

This significant investment will accelerate the company’s mission to transform cancer treatment by leveraging its unique platform of scalable, allogeneic immune cell therapies derived from cord blood.

At the heart of ImmuneBridge’s innovation lies a proprietary technology capable of expanding cord blood-derived hematopoietic stem and progenitor cells (HSPCs) over 100,000-fold while retaining full immune multipotency.

This breakthrough not only ensures a consistent and abundant source of therapeutic cells but also supports the generation of a diverse immune cell repertoire, including natural killer (NK) cells, T cells, and macrophages.

In the near term, these funds will support the clinical advancement of an expanded-HSC-derived NK cell product designed to target hematological malignancies, thereby validating both the economic and clinical potential of their expansion approach.

Looking ahead, ImmuneBridge plans to harness the inherent advantages of its agile discovery platform to tackle the formidable challenge of solid tumors through combinations of modified and unmodified cell therapies.

By reducing the costs and time associated with traditional discovery and manufacturing processes, the company can more rapidly iterate and refine its therapeutic strategies, enabling precision matches to target populations through optimal HLA typing and selective genotype enrichment.

This funding milestone not only affirms the strength and promise of ImmuneBridge’s innovative platform but also fuels its commitment to deliver safer, more effective, and accessible cancer treatments to patients worldwide.